SynthesisBiosensors2018
Olfactory Dysfunction as a Global Biomarker for Sniffing out Alzheimer's Disease: A Meta-Analysis.
Synthesis in Biosensors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Biomarkers for Alzheimer's disease across diverse biological domains: an umbrella review and evidence map.Journal of advanced research · 2026Pooled it
- Valid olfactory impairment tests can help identify mild cognitive impairment: an updated meta-analysis.Frontiers in aging neuroscience · 2024Pooled it
- The Correlation Between Olfactory Test and Hippocampal Volume in Alzheimer's Disease and Mild Cognitive Impairment Patients: A Meta-Analysis.Frontiers in aging neuroscience · 2021Pooled it
- The scent of emotions: A systematic review of human intra- and interspecific chemical communication of emotions.Brain and behavior · 2020Pooled it
- Entropy-Based Analysis of Olfactory EEG as a Candidate Biomarker for Early Mild Cognitive Impairment Detection: A Proof-of-Concept Study.Biosensors · 2026Article
- Olfactory impairment associated with cognitive decline: findings from cognitive domain assessments among older adults in West Jakarta, Indonesia.BMC geriatrics · 2026Article
- Characterizing olfaction, anxiety, and depression in subjective cognitive decline.Journal of Alzheimer's disease : JAD · 2026Article
- Granulocyte Colony Stimulating Factor (G-CSF) and Olfactory Function-A Clinical Pilot Study.Laryngoscope investigative otolaryngology · 2025Article
- Depression, Anxiety, and Neuropsychiatric Symptom Burden in a Longitudinal Cohort with Persistent Psychophysical Post-COVID Olfactory Dysfunction.Brain sciences · 2024Article
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging.Nature communications · 2024Article
- Olfactory Dysfunction and Glaucoma.Biomedicines · 2024Review
- Associations between olfactory dysfunction and cognition: a scoping review.Journal of neurology · 2024Article
- The Value of Subjective Olfactometry as a Predictive Biomarker of Neurodegenerative Diseases: A Systematic Review.Life (Basel, Switzerland) · 2024Review
- Mesenchymal Stem Cells from Familial Alzheimer's Patients Express MicroRNA Differently.International journal of molecular sciences · 2024Article
- Understanding the Prevalence and Risk Factor Profile of Olfactory Impairment and Its Impact on Patient Health Indicators and Economic Outcomes in Community-Dwelling Older Asian Adults.Innovation in aging · 2024Article
- An experimental framework for conjoint measures of olfaction, navigation, and motion as pre-clinical biomarkers of Alzheimer's disease.Journal of Alzheimer's disease reports · 2024Review
- Unraveling the Link between Olfactory Deficits and Neuropsychiatric Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Review
- Morphometric analysis of medial temporal lobe subregions in Alzheimer's disease using high-resolution MRI.Brain structure & function · 2023Article
- The Proteome Profile of Olfactory Ecto-Mesenchymal Stem Cells-Derived from Patients with Familial Alzheimer's Disease Reveals New Insights for AD Study.International journal of molecular sciences · 2023Article
- New balance capability index as a screening tool for mild cognitive impairment.BMC geriatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cases of Alzheimer's disease (AD) are rising exponentially due to increasing global life expectancy. There are approximately 50 million sufferers worldwide, with prevalence rising most rapidly in low-income countries such as Africa and Asia. There is currently no definite diagnosis of AD until after death, thus an early biomarker for AD is urgently required in order to administer timelier and more effective interventions. Olfactory dysfunction (problems with the sense of smell) is one of the earliest, preclinical symptoms observed in AD. Olfaction is a promising early biomarker for use worldwide as it is easy, cheap to measure, and not reliant on specialist clinicians or laboratory analysis. We carried out a meta-analysis to determine the credibility of olfaction in diagnosing AD in the preclinical stages, by comparing olfaction in healthy controls against AD patients and patients with mild cognitive impairment (MCI). Data from 10 articles were subjected to two comparative meta-analyses. In the case of AD, the results illustrated that the overall magnitude of effect size was more apparent,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.